Stay updated on Nivolumab and Ipilimumab in ACC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in ACC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedMinor formatting tweaks and updates to non-critical metadata were observed, and core study details such as title, NCT number, objectives, eligibility criteria, and primary outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check19 days agoNo Change Detected
- Check40 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference2%

- Check47 days agoChange DetectedExpanded immune biology content and updated version to v3.1.0, replacing the previous v3.0.2.SummaryDifference0.7%

- Check61 days agoChange DetectedThe page now shows revision v3.0.2, upgrading from v3.0.1. The 'Back to Top' link was removed, a minor UI change.SummaryDifference0.1%

- Check69 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%

- Check76 days agoChange DetectedThe web page has added significant content related to Salivary Gland Cancer, including a study on treatment options and various related medical topics, while removing several previous references to oral cancer and related diseases.SummaryDifference4%

Stay in the know with updates to Nivolumab and Ipilimumab in ACC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.